Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosuvastatin and Tim-3 expression in chronic hepatitis B
IRCT20190602043789N1Phase 4Completed
- Sponsor
- Golestan University of Medical Sciences
- Start
- Oct 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, double-blind trial of rosuvastatin in Chronic Hepatitis B (CHB) (2 arms), sponsored by Golestan University of Medical Sciences. Primary endpoints: Percentage of NK cells containing Tim-3 protein and Percentage of NKT cells containing Tim-3 protein. Started Oct 2019; status: completed.
02
Drugs
rosuvastatin
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on IRCT20190602043789N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190602043789N1.